Amplified antitumor efficacy by a targeted drug retention and chemosensitization strategy-based "combo" nanoagent together with PD-L1 blockade in reversing multidrug resistance

J Nanobiotechnology. 2021 Jul 5;19(1):200. doi: 10.1186/s12951-021-00947-9.

Abstract

Background: Recent studies have demonstrated that multidrug resistance (MDR) is a critical factor in the low efficacy of cancer chemotherapy. The main mechanism of MDR arises from the overexpression of P-glycoprotein (P-gp), which actively enhances drug efflux and limits the effectiveness of chemotherapeutic agents.

Results: In this study, we fabricated a "combo" nanoagent equipping with triple synergistic strategies for enhancing antitumor efficacy against MDR cells. Tumor homing-penetrating peptide endows the nanosystem with targeting and penetrating capabilities in the first stage of tumor internalization. The abundant amine groups of polyethylenimine (PEI)-modified nanoparticles then trigger a proton sponge effect to promote endo/lysosomal escape, which enhances the intracellular accumulation and retention of anticancer drugs. Furthermore, copper tetrakis(4-carboxyphenyl)porphyrin (CuTCPP) encapsulated in the nanosystem, effectively scavenges endogenous glutathione (GSH) to reduce the detoxification mediated by GSH and sensitize the cancer cells to drugs, while simultaneously serving as a photoacoustic imaging (PAI) contrast agent for image visualization. Moreover, we also verify that these versatile nanoparticles in combination with PD-1/PD-L1 blockade therapy can not only activate immunological responses but also inhibit P-gp expression to obliterate primary and metastatic tumors.

Conclusion: This work shows a significant enhancement in therapeutic efficacy against MDR cells and syngeneic tumors by using multiple MDR reversing strategies compared to an equivalent dose of free paclitaxel.

Keywords: Chemotherapy enhancement; Endo/lysosomal escape; Multidrug resistance; PD-L1 blockade; Tumor homing-penetrating peptide.

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • B7-H1 Antigen / metabolism
  • Cell Line, Tumor
  • Copper
  • Drug Delivery Systems / methods
  • Drug Liberation
  • Drug Resistance, Neoplasm / drug effects*
  • Drug Therapy
  • Female
  • Heterocyclic Compounds
  • Humans
  • Immune Checkpoint Inhibitors / pharmacology*
  • Lysosomes
  • MCF-7 Cells
  • Metalloporphyrins
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Nanomedicine
  • Nanoparticles / chemistry
  • Nanoparticles / therapeutic use*
  • Organophosphorus Compounds
  • Paclitaxel / pharmacology

Substances

  • Antineoplastic Agents
  • B7-H1 Antigen
  • Heterocyclic Compounds
  • Immune Checkpoint Inhibitors
  • Metalloporphyrins
  • Organophosphorus Compounds
  • tris(o-phenylenedioxy)cyclotriphosphazene
  • 5,10,15,20-tetrakis(4-carboxyphenyl)porphinatocopper(II)
  • Copper
  • Paclitaxel